Carl Decicco is a venture partner at Flagship Pioneering and chief scientific officer at Foghorn® Therapeutics, a Flagship Pioneering company. Carl brings more than 30 years of biopharmaceutical and R&D experience to both organizations.
Prior to joining Foghorn and Flagship, Carl spent 17 years at Bristol-Myers Squibb (BMS), where he most recently served as senior vice president, head of discovery since 2013 and was a member of the R&D leadership team. Carl first joined BMS as head of discovery chemistry during the DuPont Pharmaceuticals acquisition in 2001. Over his career in biopharmaceutical research, Carl has played a central role in the advancement of more than 200 compounds into clinical trials and the approval of more than 20 drugs across multiple therapeutic areas in both small molecules and biologics.
Carl has authored/co-authored more than 100 scientific papers in peer-reviewed journals, is listed as an inventor on 26 patents, and has lectured extensively at major academic and industrial institutions. Carl received his Ph.D. in organic chemistry from the Guelph-Waterloo Center in Ontario, Canada. He completed his post-doctoral studies at Harvard University, and he was a teaching fellow at the University of British Columbia. In 2018, Carl was the recipient of the Bloch Lectureship Award from the University of Chicago for his achievements and contributions to advancing science. He has served on numerous university boards.